Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo

Proteomics - Clinical Applications

Volumn 3, Issue 6, 2009, Pages 720-729

  Jenkins, Rosalind E ^a   Meng, Xiaoli ^a,b   Elliott, Victoria L ^a   Kitteringham, Neil R ^a   Pirmohamed, Munir ^a,b   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Allergens; Plasma; Protein adducts; Target for drugs

Indexed keywords

5 HYDROXYMETHYLFLUCLOXACILLIN; DRUG METABOLITE; FLUCLOXACILLIN; HAPTEN; HUMAN SERUM ALBUMIN; LYSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CATION EXCHANGE; CLINICAL ARTICLE; DRUG BINDING SITE; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN MODIFICATION; RESIDUE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; STAPHYLOCOCCUS INFECTION;

EID: 70350113458     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800222     Document Type: Article

References (33)

1. Sutherland, R., Croydon, E. A., Rolinson, G. N., Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. Br. Med. J. 1970, 4, 455-460.
2. Koek, G. H., Stricker, B. H., Blok, A. P., Schalm, S. W., Desmet, V. J., Flucloxacillin-associated hepatic injury. Liver 1994, 14, 225-229.
3. Spanou, Z., Keller, M., Britschgi, M., Yawalkar, N. et al., Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J. Am. Soc. Nephrol. 2006, 17, 2919-2927.
4. Olsson, R.,Wiholm, B. E., Sand, C., Zettergren, L. et al., Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J. Hepatol. 1992, 15, 154-161.
5. Carey, M. A., van Pelt, F. N., Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 2005, 216, 41-48.
6. Russmann, S., Kaye, J. A., Jick, S. S., Jick, H., Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br. J. Clin. Pharmacol. 2005, 60, 76-82.
7. Bjornsson, E., Jerlstad, P., Bergqvist, A., Olsson, R., Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand. J. Gastroenterol. 2005, 40, 1095-1101.
8. Lakehal, F., Dansette, P. M., Becquemont, L., Lasnier, E. et al., Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem. Res. Toxicol. 2001, 14, 694-701.
9. Baldo, B. A., Pham, N. H., Weiner, J., Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. J. Mol. Recognit. 1995, 8, 171-177.
10. Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., Park, B. K., Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 2000, 23, 483-507.
11. Warbrick, E. V., Thomas, A. L., Stejskal, V., Coleman, J. W., An analysis of beta-lactam-derived antigens on spleen cell and serum proteins by ELISA and Western blotting. Allergy 1995, 50, 910-917.
12. Greenough, C., Jenkins, R. E., Kitteringham, N. R., Pirmohamed, M. et al., A method for the rapid depletion of albumin and immunoglobulin from human plasma. Proteomics 2004, 4, 3107-3111.
13. Li, H., Robertson, A. D., Jensen, J. H., Very fast empirical prediction and rationalization of protein pKa values. Proteins 2005, 61, 704-721.
14. Jensen, J. H., Li, H., Robertson, A. D., Molina, P. A., Prediction and rationalization of protein pKa values using QM and QM/MM methods. J. Phys. Chem. A 2005, 109, 6634-6643.
15. Gordon, J. C., Myers, J. B., Folta, T., Shoja, V. et al., H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005, 33, W368-W371.
16. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G. et al., The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
17. Sugio, S., Kashima, A., Mochizuki, S., Noda, M., Kobayashi, K., Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng. 1999, 12, 439-446.
18. Harms, M. J., Schlessman, J. L., Chimenti, M. S., Sue, G. R. et al., A buried lysine that titrates with a normal pKa: role of conformational flexibility at the protein-water interface as a determinant of pKa values. Protein Sci. 2008, 17, 833-845.
19. Yamana, T., Tsuji, A., Miyamoto, E., Kiya, E., Kinetics and mechanism of penicillin aminolysis involved in penicillin allergy. J. Pharm. Pharmacol. 1975, 27, 56-57.
20. Bundgaard, H., Chemical aspect of penicillin allergy: imidazole-catalyzed isomerization of benzylpenicillin into benzylpenicillenic acid. Dan. Tidsskr. Farm. 1972, 46, 29-40.
21. Willard, L., Ranjan, A., Zhang, H., Monzavi, H. et al., VADAR: a web server for quantitative evaluation of protein structure quality. Nucleic Acids Res. 2003, 31, 3316-3319.
22. Sudlow, G., Birkett, D. J., Wade, D. N., Spectroscopic techniques in the study of protein binding. A fluorescence technique for the evaluation of the albumin binding and displacement of warfarin and warfarin-alcohol. Clin. Exp. Pharmacol. Physiol. 1975, 2, 129-140.
23. Roder, B. L., Frimodt-Moller, N., Espersen, F., Rasmussen, S. N., Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration. Infection 1995, 23, 107-112.
24. Lafaye, P., Lapresle, C., Fixation of penicilloyl groups to albumin and appearance of anti-penicilloyl antibodies in penicillin-treated patients. J. Clin. Invest. 1988, 82, 7-12.
25. Brander, C., Mauri-Hellweg, D., Bettens, F., Rolli, H. et al., Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J. Immunol. 1995, 155, 2670-2678.
26. Gath, J., Charles, B., Sampson, J., Smithurst, B., Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients. J. Clin. Pharmacol. 1995, 35, 31-36.
27. Paton, D. M., Mander, P., Avery, R. J., Bioavailability and half-life of two preparations of flucloxacillin. N. Z. Med. J. 1982, 95, 766-768.
28. Anderson, N. L., Anderson, N. G., The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
29. Muller, D., Karle, A., Meissburger, B., Hofig, I. et al., Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem. 2007, 282, 12650-12660.
30. Kitteringham, N. R., Maggs, J. L., Newby, S., Park, B. K., Drug-protein conjugates--VIII. The metabolic fate of the dinitrophenyl hapten conjugated to albumin. Biochem. Pharmacol. 1985, 34, 1763-1771.
31. Weber, H. K., Zuegg, J., Faber, K., Pleissb, J., Molecular reasons for lipase-sensitivity against acetaldehyde. J. Mol. Catal. B-Enzym. 1997, 3, 131.
32. Fasano, M., Curry, S., Terreno, E., Galliano, M. et al., The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005, 57, 787-796.
33. He, X. M., Carter, D. C., Atomic structure and chemistry of human serum albumin. Nature 1992, 358, 209-215.